The dysregulated expression of SENP1 has been implicated in the pathogenesis of various cancers, including colon cancer [14], prostate cancer [15, 16], etc. Moreover, SENP1 specific inhibitors have shown promising therapeutic effects in a variety of cancers, which suggested that SENP1 may be an effective potential therapeutic target in the treatment of cancers. This evidence concerns the gene SENP1 and prostate carcinoma.